Recombinant human interferon-α14 for the treatment of canine allergic pruritic disease in eight dogs.
allergic
atopic dermatitis
dog
interferon
pruritic diseases
Journal
Veterinary record open
ISSN: 2052-6113
Titre abrégé: Vet Rec Open
Pays: United States
ID NLM: 101653671
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
08
06
2020
revised:
15
01
2021
accepted:
03
02
2021
entrez:
13
5
2021
pubmed:
14
5
2021
medline:
14
5
2021
Statut:
epublish
Résumé
Allergic pruritic diseases are increasingly common in dogs. This group of conditions hampers life quality as pruritus progressively interferes with normal behaviours. Therefore, new treatment modalities for canine allergic pruritic diseases are necessary. While novel drugs have recently reached the market, there is still the need for other therapeutic approaches. Some dogs are refractory even to the newer compounds, and cost is also an important issue for these. Older therapeutic modalities are only moderately successful or have considerable secondary effects, as is the case with glucocorticoids. Report on the use of recombinant human interferon-α14 (rhIFN-α14) for the treatment of canine allergic pruritus. Following the experience with a similar compound in the Japanese market, it was expected that rhIFN-α14 could alter the Th1/Th2 disbalance that drives these diseases. Here, we present an uncontrolled trial in which eight dogs with clinical diagnosis of allergic pruritus were treated with rhIFN-α14, either orally or via subcutaneous injections. Skin condition, microbiota and anti-interferon antibody levels were assessed. The parenteral use of interferon induced hypersensitivity in two of the three dogs in which it was used. The oral administration was consistently safe and could reduce signs of the allergic condition in three of the five treated animals. Treatment also altered the skin microbiota, as verified by next-generation sequencing. The present results indicate that rhIFN-α14 is a viable candidate for the treatment of canine allergic pruritus. Future controlled studies are needed, and the oral route is indicated for further trials.
Sections du résumé
BACKGROUND
BACKGROUND
Allergic pruritic diseases are increasingly common in dogs. This group of conditions hampers life quality as pruritus progressively interferes with normal behaviours. Therefore, new treatment modalities for canine allergic pruritic diseases are necessary. While novel drugs have recently reached the market, there is still the need for other therapeutic approaches. Some dogs are refractory even to the newer compounds, and cost is also an important issue for these. Older therapeutic modalities are only moderately successful or have considerable secondary effects, as is the case with glucocorticoids.
OBJECTIVES
OBJECTIVE
Report on the use of recombinant human interferon-α14 (rhIFN-α14) for the treatment of canine allergic pruritus. Following the experience with a similar compound in the Japanese market, it was expected that rhIFN-α14 could alter the Th1/Th2 disbalance that drives these diseases.
METHODS
METHODS
Here, we present an uncontrolled trial in which eight dogs with clinical diagnosis of allergic pruritus were treated with rhIFN-α14, either orally or via subcutaneous injections. Skin condition, microbiota and anti-interferon antibody levels were assessed.
RESULTS
RESULTS
The parenteral use of interferon induced hypersensitivity in two of the three dogs in which it was used. The oral administration was consistently safe and could reduce signs of the allergic condition in three of the five treated animals. Treatment also altered the skin microbiota, as verified by next-generation sequencing.
CONCLUSION
CONCLUSIONS
The present results indicate that rhIFN-α14 is a viable candidate for the treatment of canine allergic pruritus. Future controlled studies are needed, and the oral route is indicated for further trials.
Identifiants
pubmed: 33981440
doi: 10.1002/vro2.6
pii: VRO26
pmc: PMC8109859
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e6Informations de copyright
© 2021 The Authors. Veterinary Record Open published by John Wiley & Sons Ltd on behalf of British Veterinary Association.
Références
Acta Derm Venereol. 1992 Sep;72(5):370-2
pubmed: 1361287
J Interferon Cytokine Res. 1999 Aug;19(8):901-5
pubmed: 10476936
BMC Vet Res. 2015 Aug 16;11:210
pubmed: 26276051
J Invest Dermatol. 2020 May;140(5):1066-1074.e4
pubmed: 31877319
Vet Microbiol. 2019 Feb;229:90-99
pubmed: 30642603
Vet Dermatol. 2013 Oct;24(5):479-e114
pubmed: 23829933
Vet Dermatol. 2003 Jun;14(3):121-46
pubmed: 12791047
Vet Immunol Immunopathol. 2014 Jan 15;157(1-2):42-8
pubmed: 24321252
J Allergy Clin Immunol. 2016 Jan;137(1):130-136
pubmed: 26253344
Front Vet Sci. 2017 Feb 06;4:6
pubmed: 28220148
Vet Dermatol. 2016 Oct;27(5):332-e82
pubmed: 27485242
N Engl J Med. 1988 Jun 2;318(22):1409-13
pubmed: 3367950
PLoS Pathog. 2021 Mar 10;17(3):e1009387
pubmed: 33690673
MAbs. 2015;7(4):662-71
pubmed: 25962087
J Investig Allergol Clin Immunol. 2014;24(4):212-25; quiz 1p following 225
pubmed: 25219103
J Vet Intern Med. 2012 Jul-Aug;26(4):863-74
pubmed: 22519673
Am J Vet Res. 2006 Aug;67(8):1406-11
pubmed: 16881854
J Invest Dermatol. 2016 Jun;136(6):1182-1190
pubmed: 26854488
Cytokine. 2014 Mar;66(1):54-9
pubmed: 24548425
Expert Opin Biol Ther. 2016;16(4):507-14
pubmed: 26694988
Ann Dermatol. 2011 Feb;23(1):1-11
pubmed: 21738356
Vet Immunol Immunopathol. 2001 Sep 20;81(3-4):317-22
pubmed: 11553394
PeerJ. 2017 Mar 9;5:e3075
pubmed: 28289569
Vet Dermatol. 2006 Jun;17(3):195-200
pubmed: 16674735
Vet Immunol Immunopathol. 2006 Feb 15;109(3-4):245-54
pubmed: 16169599
J Vet Pharmacol Ther. 2014 Aug;37(4):317-24
pubmed: 24495176
Vet Immunol Immunopathol. 2001 Sep 20;81(3-4):147-51
pubmed: 11553375
Vet Dermatol. 2010 Feb;21(1):42-9
pubmed: 19706009